

## We Claim:

1. A composition comprising a TNF- $\alpha$  binding molecule, or a nucleic acid sequence encoding a TNF- $\alpha$  binding molecule, wherein said TNF- $\alpha$  binding molecule comprises; i) a CDRL3 sequence comprising SEQ ID NO: 33, and ii) a CDRH3  
5 comprising SEQ ID NO: 53.

2. The composition of Claim 1, wherein said TNF- $\alpha$  binding molecule further comprises iii) a CDRL1 sequence comprising SEQ ID NO: 15, and iv) a CDRL2  
10 sequence comprising SEQ ID NO: 25.

3. The composition of Claim 2, wherein said TNF- $\alpha$  binding molecule further comprises v) a CDRH1 sequence comprising SEQ ID NO: 37, and vi) a CDRH2  
15 sequence comprising SEQ ID NO: 45.

4. The composition of Claim 2, wherein said TNF- $\alpha$  binding molecule further comprises v) a CDRH1 sequence comprising SEQ ID NO: 39, and vi) a CDRH2 sequence  
comprising SEQ ID NO: 45.

5. The composition of Claim 1, wherein said TNF- $\alpha$  binding molecule further comprises iii) a CDRL1 sequence comprising SEQ ID NO: 13, and iv) a CDRL2  
20 sequence comprising SEQ ID NO: 27.

6. The composition of Claim 5, wherein said TNF- $\alpha$  binding molecule further comprises v) a CDRH1 sequence comprising SEQ ID NO: 37, and vi) a CDRH2  
25 sequence comprising SEQ ID NO: 55.

7. The composition of Claim 1, wherein said TNF- $\alpha$  binding molecule further comprises a light chain variable region, wherein said light chain variable region  
30 comprises a human germline framework region.

8. The composition of Claim 1, wherein said TNF- $\alpha$  binding molecule further comprises a heavy chain variable region, wherein said heavy chain variable region  
comprises a human germline framework region.

9. A composition comprising a TNF- $\alpha$  binding, or a nucleic acid sequence encoding a TNF- $\alpha$  binding molecule, wherein said TNF- $\alpha$  binding molecule neutralizes human TNF- $\alpha$  cytotoxicity in an in vitro, cell-based assay with an EC<sub>50</sub> of  $2.0 \times 10^{-11}$  or less.

5

10. The composition of Claim 9, wherein said TNF- $\alpha$  binding molecule has a binding affinity ( $K_d$ ) for human TNF- $\alpha$  of  $7.5 \times 10^{-12}$  M or less.

11. The composition of Claim 9, wherein said TNF- $\alpha$  binding molecule has an association rate ( $k_{on}$ ) for human TNF- $\alpha$  of  $3.0 \times 10^6$  M<sup>-1</sup> s<sup>-1</sup> or greater.

10

12. The composition of Claim 9, wherein said TNF- $\alpha$  binding molecule has a dissociation rate ( $k_{off}$ ) for human TNF- $\alpha$  of  $1.0 \times 10^{-4}$  s<sup>-1</sup> or less.

15

13. The composition of Claim 9, wherein said TNF- $\alpha$  binding molecule comprises a light chain variable region, wherein said light chain variable region comprises a human germline framework region.

14. The composition of Claim 9, wherein said TNF- $\alpha$  binding molecule comprises a heavy chain variable region, wherein said heavy chain variable region comprises a human germline framework region.

20

15. A method treating a TNF- $\alpha$  mediated disease comprising;

a) providing;

25

i) a subject, and

ii) a composition, wherein said composition comprises TNF- $\alpha$  binding molecules that neutralize human TNF- $\alpha$  cytotoxicity in an in vitro, cell-based assay with an EC<sub>50</sub> of  $2.0 \times 10^{-11}$  or less; and

b) administering said composition to said subject.

30

16. The method of Claim 15, wherein said TNF- $\alpha$  mediated disease is selected from sepsis, an autoimmune disease, and rheumatoid arthritis.

17. The method of Claim 15, wherein said TNF- $\alpha$  binding molecules have a binding affinity ( $K_d$ ) for human TNF- $\alpha$  of  $7.5 \times 10^{-12}$  M or less.

18. The method of Claim 15, wherein said TNF- $\alpha$  binding molecules have an association rate ( $k_{on}$ ) for human TNF- $\alpha$  of  $3.0 \times 10^6$  M<sup>-1</sup> s<sup>-1</sup> or greater.

19. The method of Claim 15, wherein said TNF- $\alpha$  binding molecules have a disassociation rate ( $k_{off}$ ) for human TNF $\alpha$  of  $1.0 \times 10^{-4}$  s<sup>-1</sup> or less.

20. The method of Claim 15, wherein said TNF- $\alpha$  binding molecule comprises a light chain variable region, wherein said light chain variable region comprises a human germline framework region.

21. The method of Claim 15, wherein said TNF- $\alpha$  binding molecule comprises a heavy chain variable region, wherein said heavy chain variable region comprises a human germline framework region.

22. A composition comprising a TNF- $\alpha$  binding molecule, or a nucleic acid sequence encoding a TNF- $\alpha$  binding molecule, wherein said TNF- $\alpha$  binding molecule comprises at least one of the following CDR sequences; i) a CDRL1 sequence comprising SEQ ID NO:93; ii) a CDRL2 sequence comprising SEQ ID NO:95; iii) a CDRL3 sequence comprising SEQ ID NO: 97; iv) a CDRH1 sequence comprising SEQ ID NO:87; v) a CDRH2 sequence comprising SEQ ID NO:89, and vi) a CDRH3 sequence comprising SEQ ID NO: 91.

23. The composition of Claim 22, wherein said TNF- $\alpha$  binding molecule comprises at least three of said CDR sequences.

24. The composition of Claim 22, wherein said TNF- $\alpha$  binding molecule comprises all six of said CDR sequences.